• 内刊赠阅
  • |
  • |
  • 行业内参
  • |
  • 帮助中心
  • |
  • 关于我们
  • |
注 册
中国+86
  • +123
  • +125
  • +666
  • +666
  • +555555
  • +666
  • +666
  • +666
请输入真实手机号
请输入图片验证码
请输入短信验证码
请输入密码

已有账号,

忘记密码
中国+86
  • +123
  • +125
  • +666
  • +666
  • +555555
  • +666
  • +666
  • +666
请输入真实手机号
请输入图片验证码
请输入短信验证码
请输入新密码

已有账号,

当前位置: 艾媒报告中心 > 大健康

本报告研究涉及企业/品牌/案例:同仁堂、香雪制药、白云山。

数据显示,2020年第三季度,中药材价格指数迎来上涨周期。艾媒咨询分析师认为,受动物类等少数品种拉动影响,预计2020年10-11月中药材指数会持续走高,但是在12月维稳。据调查,绝大多数商户将会在2021年密切关注行业相关政策、谨慎经营,采取减少压货炒作等经营方式。因而,预计中药材市场在2020年末旺季会有一波行情的走高,但随着旺季结束,明年年初的价格会重新回落,随着疫情的常态化,中药材市场行情预期会呈周期性波动的态势。

Data show that in the third quarter of 2020, Chinese Herbal Medicine Price Index ushered in an upward cycle. iiMedia Research believe that by a small number of animals and other species pull the impact of October 2020-november Chinese herbal medicine index is expected to continue to rise, but stable in December. According to the survey, the vast majority of businesses in the 2021 will pay close attention to industry-related policies, prudent management, to reduce speculation and other business practices. As a result, the Chinese herbal medicine market is expected to see a wave of rising prices in the peak season at the end of 2020. However, as the peak season ends, prices will fall back early next year, and as the epidemic becomes more normal, chinese medicinal materials market is expected to be cyclical fluctuations in the situation.

本报告研究涉及企业/品牌/案例:宝贝格子、孩子王、优家宝贝。

新冠疫情的爆发激发了母婴行业对转型升级紧迫性、重要性的认知,成为了线上线下加速融合的助推器。目前连锁母婴品牌的线下发展已经呈现出一定的分化,少数品牌凭借轻资产扩张模式取得了亮眼表现。艾媒咨询分析师认为,在母婴消费品质升级的长期趋势下,线下实体母婴门店在逐步品牌化、连锁化的同时也将延伸线上业务,通过线上服务增强顾客粘性。而对于布局线上的母婴企业,疫情期间以直播为代表的线上营销方式起势正猛,有望走向常态化。艾媒咨询分析师认为,供需侧的变化加速了母婴产业线上线下融合, 母婴新零售体系日趋完善。在母婴新零售业态不断发展的过程中,持续升级产品服务,才是母婴新零售企业长续经营的关键。

The outbreak of coVID19 has aroused the awareness of the urgency and importance of transformation and upgrading in the maternal and infant industry, which has become a booster for accelerating the integration of online and offline industries. At present, the offline development of chain maternal and infant brands has presented a trend of differentiation, and a few brands have made a bright performance by virtue of the assetlight expansion mode. iiMedia consulting analyst believes that under the long-term trend of upgrading the consumption quality, offline brick-and-mortar stores for mothers and infants will gradually become branded and chain-store. Meanwhile they would extend their online business and using online services to enhance customer stickiness. For online maternal and child enterprises, the online marketing represented by live broadcast during the epidemic is gaining momentum and is expected to be normalized. iiMedia consulting analyst believes that the changes on the supply and demand side have accelerated the online and offline integration of the maternal and infant industry. The new maternal and infant retail system is becoming more and more complete. In the process of the development of maternal and infant new retail business, the continuous upgrading of products and services is the key.

本报告研究涉及企业/品牌/案例:华夏源、复星医药。

中国细胞生物产业类型呈现多样化趋势,细胞生物临床研究不断深化,伴随生态合作的拓展将进一步加速细胞生物产业生态圈的形成,生态圈的完善将在很大限度上推动产业快速发展。数据显示,中国细胞治疗企业融资金额不断增加,从2014年的0.2亿元增长至2019年的28.9亿元。其中,2018年中国细胞治疗企业融资额同比增长706.8%,呈现迅猛发展态势。未来中国细胞生物产业的发展将充满机遇,同时也有挑战并存。后续产业的发展,将在5G、人工智能等新技术应用下加速升级。面临多端变化的市场格局,企业也应积极开展生态合作以及更为密切关注市场需求动向,将疗法和新一代医疗创新技术深度融合,实现市场产品多元化与差异化,并推出独特性的精准治疗,从而最大限度地释放产业价值。

The types of cell biological industry in China show a trend of diversification, and the deepening of cell biological clinical research will further accelerate the formation of the cell biological industry ecosystem with the expansion of ecological cooperation, and the improvement of the ecosystem will promote the rapid development of the industry to a large extent. Data show that the financing amount of Chinese cell therapy enterprises keeps increasing, from 20 million yuan in 2014 to 2.89 billion yuan in 2019. Among them, in 2018, the financing amount of Chinese cell therapy enterprises increased by 706.8% year on year, showing a rapid development trend. In the future, the development of China's cell biology industry will be full of opportunities and challenges. The development of subsequent industries will be accelerated with the application of new technologies such as 5G and ARTIFICIAL intelligence. In the face of the changing market pattern, enterprises should also actively carry out ecological cooperation and pay close attention to the trend of market demand, deeply integrate therapy and new-generation medical innovation technology, realize the diversification and differentiation of market products, and launch unique precision therapy, so as to maximize the release of industrial value.


在线
客服